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Exosomes are 40–100nm membrane vesicles secreted into
the extracellular space by numerous cell types. These
structures can be isolated from body fluids including urine
and plasma. Exosomes contain proteins, mRNAs, miRNAs,
and signaling molecules that reflect the physiological state of
their cells of origin and consequently provide a rich source of
potential biomarker molecules. Aside from diagnostic uses,
exosome-mediated transfer of proteins, mRNAs, miRNAs, and
signaling molecules offer the promise that they may be used
for therapeutic purposes. In this review, we integrate new
knowledge about exosomes from outside the field of
nephrology with recent progress by renal researchers in
order to provide a basis for speculation about how the study
of exosomes may affect the fields of nephrology and renal
physiology in the next few years.
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Over the past several years, there has been increasing interest
in the nephrology community in a newly recognized
biological entity, namely, the exosome. Exosomes are small
(40–100 nm) membrane-bound vesicles, secreted upon fusion
of the limiting membrane of multivesicular bodies with the
plasma membrane.1 Besides the vesicular exosome, there is an
entirely different structure in eukaryotic cells that is called
an ‘exosome’, that is, the RNA–exosome, a multi-protein
complex that degrades various types of RNA molecules.2
Vesicular exosomes are also referred to as microvesicles in
some works. As discussed in this article, vesicular exosomes
may contain RNA exosomes. For simplicity, we use the term
‘exosome’ to refer to ‘vesicular exosomes’ throughout. They
are present not only in urine3 but also in a variety of other
body fluids including blood plasma.1 On the basis of protein
mass spectrometry (MS) results, urinary exosomes appear to
derive from each of the epithelial cell types facing the renal
tubule lumen.3 Similarly, exosomes in plasma most likely
derive from the many cell types that face the vascular lumen,
including various types of blood cells and endothelial cells.
We have previously published reviews on the topic of urinary
exosomes, focusing mainly on the isolation of urinary
exosomes as the starting material for protein biomarker
discovery experiments.4–7 Here we take a broader view, with
an attempt to integrate progress outside of the field of
nephrology with recent progress by renal researchers to
provide a basis for speculation about what impact the study
of exosomes will have on the fields of nephrology and renal
physiology in the next few years.
BIOLOGY OF EXOSOMES
In 1981, Trams et al.8 proposed the term ‘exosomes’ for
exfoliated membrane vesicles, appearing as large
(500–1000 nm) and small (approximately 40 nm) vesicles,
which they identified to be secreted by a variety of cell types.
A few years later, Johnstone et al.9 discovered that during
reticulocyte maturation, specific proteins, including the
transferrin receptor, are shed via secretion of o100 nm
vesicles that they termed ‘exosomes’. In the current literature,
exosomes are defined as 40–100 nm vesicles that are secreted
upon fusion of multivesicular bodies (late endosomes) with
the plasma membrane. This fusion event results in the release
of the intraluminal vesicles of multivesicular bodies, after
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which they are termed ‘exosomes’, into the extracellular
space.1 Exosomes are known to be produced by many
different cell types, including dendritic cells, B-lymphocytes,
various stem cells, epithelial cells, and endothelial cells,3,10–15
and can be isolated from cell culture supernatant, as well as
from a variety of biological fluids, such as blood, urine,
semen (prostasomes), amniotic fluid, and pleural
fluid.3,14,16–19 Multivesicular bodies are late endosomes that
are populated with intraluminal vesicles by fusion of small
cytoplasmic vesicles derived from early endosomes with the
outer membranes of multivesicular bodies, followed by
invagination of the recruited membrane, inward budding,
and scission (Figure 1). These events are mediated through
the concerted action of the so-called ESCRT complexes
(endosomal complexes required for transport).20,21 As
vesicles bud inward, the lumina of these future exosomes
capture a small portion of the cytosol, taking along a set of
soluble proteins, mRNAs, microRNAs (miRNAs), and other
cytosolic molecules. The orientation of the lipid membranes
of exosomes is identical to that of cells; that is, integral
membrane proteins are oriented such that the amino acid
sequences facing the outside of the plasma membrane of cells
also face to the outside of exosomes.1 It has been proposed
that in addition to random selection of a portion of the
cytoplasm, proteins and RNA molecules may be selectively
incorporated into exosomes.22–24
Besides exosomes, other types of microvesicles can also be
isolated from cell culture supernatants and body fluids
(reviewed by Camussi et al.25). These microvesicles are not
derived from multivesicular bodies, but appear to be shed by
the plasma membrane. Usually, these microvesicles tend to be
larger in size (up to 1 mm), although smaller microvesicles,
which fall in the range of exosomes, have been described.26 In
addition, it has been shown that there are microvesicles in
urine that are derived from microvilli of podocytes.27 Because
of the overlap in size, microvesicles may be included among
exosomes when they are isolated from urine.
Proteomic analyses show that many of the proteins
detectable in exosomes are common to exosomes from all
cell types.3,13,28 These include ribosomal components,
cytoskeletal proteins, small and heterotrimeric GTPases,
tetraspanin proteins, and the components of the ESCRT
complexes involved in forming multivesicular bodies.
Furthermore, exosomes contain many cell-specific proteins.
The incorporation of certain proteins into internal vesicles of
multivesicular bodies is not a random selection of proteins
expressed in a given cell type. For example, proteomic
profiling of proteins in urinary exosomes revealed an
abundance of integral membrane proteins targeted to the
apical plasma membranes of epithelial cells, but a dearth of
proteins associated with the basolateral domain.3 Further
evidence for selective protein sorting to exosomes comes
from the observations in nonpolarized cells showing that
particular proteins are enriched in exosomes compared with
the whole cell. Such proteins include the transmembrane
proteins CD55, CD59, CD63, CD81, CD82, the transferrin
receptor, and phospholipase D2, as well as many soluble
proteins such as certain heatshock proteins.14,22,23,29,30
Ubiquitin- and lipid raft-associated protein sorting have
been reported to be involved in this selective incorporation of
proteins into exosomes.28,31
PHYSIOLOGICAL ROLES OF EXOSOMES
Besides a likely role in elimination of excess or senescent
proteins and lipids, there is considerable evidence that
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Figure 1 | Exosomes in urine. (a) Electron micrograph of
negatively stained urinary exosomes (scale bar, 50 nm).
(b) Electron micrograph of a renal inner medullary collecting duct
cell (scale bar, 100 nm). Uncoated vesicles (asterisks) and coated
vesicles (arrow) are indicated. MVB, multivesicular body.
(c) Schematic of urinary exosome formation and release into the
urine. AP, adaptor protein; ALIX, ALG-2 interacting protein X;
CCP, clathrin-coated pit (clathrin molecules are shown in green);
E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating
enzyme; E3, ubiquitin-protein ligase; ESCRT, endosomal sorting
complex required for transport; ILVs, intraluminal vesicles;
Ub, ubiquitin; Vps4, vacuolar protein sorting 4. (d and e) Electron
microscope images of the 17,000 g pellets from pooled normal
human urine. Tamm–Horsfall protein (THP) forms long polymeric
filaments that are associated laterally to form rope-like structures
(d, scale bar, 800 nm and e, depicting the dashed box in d;
scale bar, 100 nm). The THP network depicted contains small
(40–100 nm) vesicles compatible with exosomes (e, arrowheads).
Kidney International (2011) 80, 1138–1145 1139
BWM van Balkom et al.: Exosomes and the kidney m in i rev iew
exosomes can have roles in intercellular signaling in a cell-
selective manner.32–36 This role has been reviewed recently by
Camussi et al.25 in this journal. Exosomes may elicit effects
on target cells by at least three possible mechanisms
(Figure 2): (I) They can adhere with high specificity to the
target cell surface (without membrane fusion) through
adhesion molecules and receptors present on their surfaces,
leading to receptor activation and downstream signaling in
the target cell.33,37 (II) Exosomes could hypothetically fuse
directly with target cells, resulting in transfer of the contents
of exosomes (mRNAs, miRNAs, proteins, and signaling
molecules). (III) Another possibility that is better supported
in the literature is that the contents of exosomes may
incorporate into target cells after endocytosis of exosomes
and processing in the endosomal pathway.34–36,38
These mechanisms have been demonstrated in exosomes
secreted into the blood and extracellular fluid. If urinary
exosomes can carry out intercellular signaling in the same
way as exosomes secreted into blood and extracellular fluid,
they could have important roles in renal physiology. For
example, exosomes may mediate downstream information
transfer in the process of renal tubule hypertrophy seen with
nephron loss. In this process, increases in single-nephron
glomerular filtration rate are matched by increases in the
transport capacity for salt and water in downstream nephron
segments, in association with marked enlargement of renal
tubule cells and widening of the tubule lumen.39 It is possible
that such downstream information transfer is occurring in
normal physiological states. Indeed, proteins that are
nominally proximal tubule proteins have been detected in
the renal-collecting duct, including the water channel
aquaporin-1 (ref. 40) and the ammonium-generating enzyme
glutaminase.41,42 Such downstream information transfer may
not always be beneficial. We speculate that Tamm–Horsfall
protein (uromodulin), an abundant polymeric protein in
normal urine, has a role to limit exosomal fusion in
downstream nephron segments. Urinary exosomes are
typically shrouded by large polymeric fibers formed from
Tamm–Horsfall protein, which would prevent them from
coming into contact with cell surfaces unless the polymeric
network is locally dissolved.43 If these speculations are true,
they may provide a basis for understanding how mutations
or deficiency of Tamm–Horsfall protein could cause renal
disease44,45 and could therefore warrant further investigation.
An additional way that urinary exosomes could have roles
in kidney physiology is through actions of exosome-resident
proteins in the renal tubule lumen. An example of this may
be the demonstrated presence of abundant angiotensin-
converting enzyme in urinary exosomes,3,46 which could have
a role in the well-known intraluminal renin–angiotensin
system described by Navar et al.47
It is certainly possible that the main physiological role for
urinary exosomes is the disposal of senescent proteins from
cells, which may be a more efficient means of protein
elimination than proteasomal degradation and lysosomal
degradation.
Although the major focus of this article is on urinary
exosomes, it is likely that exosomes secreted into the blood
and extracellular fluid have roles in renal physiology and
pathophysiology, especially among cell types with their
plasma membranes in direct contact with the vascular
compartment such as cells of the immune system and
endothelial cells. Prime examples are the roles of exosomes
and microvesicles in cell–cell communication in immune cell
and stem cell signaling. For example, exosome-mediated
communication is involved in the priming of CD8þ and
CD4þ cells by antigen-loaded major histocompatibility
complex class I and II molecules on exosomes, showing target
cell-specific effects.48,49 Receptor–ligand interaction between
exosomes and cells are also essential to identify specific target
cells, as demonstrated by the specific binding of dendritic
cell-derived exosomes to activated, and not resting, T cells.
The selection of the target cell is mediated by the interaction
between inter-cellular adhesion molecule 1 on exosomes and
its ligand, lymphocyte function-associated antigen 1, on
activated T cells,32 suggesting a mechanism by which, on a
broader scale, exosomes may be targeted to specific cell types.
In addition, it has been demonstrated that mesenchymal
stem cells contain specific miRNA signatures, which are
selectively incorporated and subsequently transferred to
target cells.50 Transferred miRNAs affect gene expression in
target cells51, demonstrating that besides transfer of proteins,
exosomes can modulate the physiology of the target cell by
transfer of RNA. Further examples for the role of micro-
vesicle-mediated transfer of RNA include the modulation of
stem cells and the stem cell niche, which could be a crucial
stem in stem cell-mediated tissue repair (reviewed by
Deregibus et al.52 and Quesenberry et al.53), and potentially
represent a system that is efficiently hijacked by tumors for
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Figure 2 |Mechanisms for exosome-mediated signaling to
target cells. Interaction of exosome surface proteins with
adhesion molecules or receptors on target cells can initiate a
downstream signaling cascade (I). Direct fusion of the exosome
membrane with the target cell plasma membrane results in the
release of content (RNA, proteins) into the cytoplasm of the target
cell (II). Transfer of exosome content to the cytoplasm may also
occur after endocytosis and subsequent fusion of the exosome
membrane with the endosomal membrane (III).
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the stimulation of angiogenesis. Blood-borne exosomes may
also be involved in angiogenesis, at least in tumors.
Specifically, tumors promote their vascularization not only
through the secretion of known angiogenic cytokines and
growth factors, but also via exosomes.38,54,55 On the basis of
these observations and others, one could well imagine that
blood-borne exosomes could have a role in various
glomerulopathies in graft rejection, in hypertension, and in
other kidney-related diseases.
EXOSOMES AS A SOURCE OF PROTEIN BIOMARKERS
Urinary proteomics studies have identified potential urinary
biomarkers for several pathological entities, for example,
acute kidney transplant rejection56 and diabetic nephro-
pathy.57 Despite these and other successes, the number of
kidney-derived proteins and peptides detectable in whole
urine (or ‘minimally processed’ urine) by MS has been
limited in part by the presence of filtered plasma proteins and
very abundant kidney-derived proteins, especially Tamm–-
Horsfall protein or uromodulin. Abundant proteins compete
with less abundant proteins for identification in the mass
spectrometer. Consequently, we may be missing the biomar-
ker candidates that would provide the best sensitivity and
specificity for diagnosis of a given disease. One approach to
enrichment of kidney-derived proteins has been the isolation
of exosomes from urine.3 Normal urine contains exosomes
that derive from every epithelial cell type facing the urinary
space (Figure 1), offering the potential to monitor physio-
logical and pathophysiological changes throughout the
nephron through the expedient of urine collection and
analysis.
The advent of detailed protein sequence data from the
human genome project and marked technological improve-
ments in MS of proteins and peptides may lead to the
discovery of even more protein biomarkers. It has become
possible to identify and quantify literally thousands of
proteins from a single sample using shotgun proteomics
based on MS systems that combine liquid chromatography
and tandem mass spectrometry (MS/MS). We have used
liquid chromatography–MS/MS-based protein MS to carry
out large-scale profiling of proteins present in urinary
exosomes from normal humans46 and have made the data
available on a publicly accessible database (http://dir.nhlbi.
nih.gov/papers/lkem/exosome/). This database provides a
listing of 1160 proteins present in urinary exosomes and
contains potential biomarker proteins that can be the basis of
hypotheses regarding the mechanism of the disease.
A general analysis of urinary proteins by Adachi et al.58
also detected large numbers of membrane proteins, pre-
sumably because of the presence of exosomes in the samples.
About 3% of total urinary protein in samples from normal
subjects is derived from exosomes.59 Thus, isolating exo-
somes from urine provides a more than 30-fold enrichment
of exosomal proteins, allowing proteins that are minor
components of whole urine to be readily detectable
immunochemically or by protein MS.
As noted above, exosomes are not uniquely found in urine
and in fact have been identified in multiple body fluids
including blood plasma, where they derive from reticulocytes,
leukocytes, endothelial cells, and presumably other cell types
that contact the intravascular space. Their presence in blood
therefore offers an advantage for biomarker discovery in
plasma, which is analogous to their advantage for biomarker
discovery in urine. Specifically, the isolation of exosomes
allows marked enrichment of biomarkers that may not be
readily detectable in whole plasma or even plasma that has
been stripped of its most abundant soluble proteins. Major
efforts have been undertaken to define the proteomes of
plasma-derived exosomes and exosomes from other body
fluids, aiming especially at the discovery of novel biomarkers
for prevalent diseases such as cancer and athero-
sclerosis.16,18,60–62 A general database of exosomal proteins
called ‘ExoCarta’ can be found at exocarta.ludwig.edu.au/.63
What disease processes in the kidney would be the best
targets for exosome-based biomarker discovery? The answer,
we believe, is ‘those diseases that require clinical decision
making, that is, currently non-optimal or too slow with
current diagnostic methodologies’. Therefore, there may be
renal diseases that are prevalent and have large negative
impacts on length or quality of life, but are not good targets
for urinary exosome-based biomarker discovery because the
addition of a new biomarker would not significantly
influence clinical decision making. On the basis of these
considerations, one example of a good target for biomarker
discovery in urinary exosomes may be the decision-making
process encountered in renal allograft patients who experi-
ence an increase in serum creatinine levels. The discrimina-
tion between rejection and kidney injury, as well as the
discrimination between different mechanisms of rejection, is
generally addressed through renal biopsy for which a full
battery of analyses generally requires many hours or days.
Here, a rapid immunological test could speed the initiation
of appropriate therapy. Another prime target is early
diagnosis of acute kidney injury in surgical and intensive
care settings. In studies reported thus far, several potential
markers have been identified including KIM1,64 HSP72,65
Klotho,66 IL-6,67 NGAL,68 L-FABP,69 netrin-1,70 or fetuin-A.71
Among these, only the study identifying fetuin-A as a
potential acute kidney injury biomarker was conducted using
exosomes as starting materials. Exosome analysis may also be
useful for classification of other disease processes involving
the renal tubule, such as polycystic kidney disease,72
lysosomal storage diseases (for example, Nieman–Pick disease
and cystinosis), and transporter mutations (such as Gitelman
and Bartter syndromes46). Urinary exosome analysis may also
be useful in the detection and classification of liver damage,
which can secondarily affect the kidney.73 In addition, it has
been proposed that analysis of urinary exosomes could be
performed in patients with hypertension,74 possibly to find
biomarkers to predict which drugs will be the most effective
in lowering the blood pressure in a given patient (person-
alized medicine). Multiple transcription factors have been
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found in urinary exosomes and their analysis has been
proposed as a means of noninvasively detecting and
monitoring various glomerular diseases including focal
segmental glomerulosclerosis.75 Furthermore, it has been
proposed that exosome analysis of urine may provide better
ways to monitor responses to the treatment of prostatic
cancer.76 The above list of biomarker targets is not
exhaustive, and other prime clinical decision-making pro-
cesses that are amenable to urinary exosome-based biomarker
discovery may be readily apparent to the reader.
Genetic diseases may also be diagnosable through urinary
exosome analysis. Looking towards the future, the continual
improvement in mass spectrometers is making it more and
more feasible to use MS in de novo sequencing mode to
screen for mutations and polymorphisms that affect the
primary sequence of proteins. Thus, although significant
strides are currently being made with regard to DNA
sequencing using so-called ‘deep-sequencing technologies’,
MS may provide an alternative way to discover sequence
variations in proteins that appear in the urinary exosomal
proteome.
EXOSOMES AS A SOURCE OF RNA BIOMARKERS
Besides proteins and peptides, exosomes contain mRNA and
miRNAs.1,28,34,77–79 Such RNAs are potentially useful as
disease biomarkers. Although efficient exosome isolation
protocols have been introduced for urinary RNA analysis,79
most studies of urinary RNAs thus far have bypassed
exosome isolation, opting for direct analysis of mRNA levels
using RT-PCR in sediments from whole urine, which
undoubtedly contains RNA from both exosomes and whole
cells. An example is a recent study showing increased
glycoprotein B7-1 to nephrin mRNA ratios in urinary
sediments from patients with minimal change disease
compared with focal segmental glomerulosclerosis.80 Another
recent example is the finding that urinary granzyme A mRNA
levels can potentially distinguish patients with cellular
rejection from those with acute kidney injury.81 Exosome
isolation can potentially increase the sensitivity and precision
of urinary mRNA analysis.
MicroRNA profiling can also be used to identify potential
biomarkers. Initially, exosomes from tumors were investi-
gated for the presence of biomarkers, and in 2008, Skog
et al.38 discovered that mRNA encoding a specific variant of
the VEGF-receptor (VEGFvIII) predicts a better treatment
response in the treatment of glioblastoma. Furthermore,
miRNA signatures of circulating exosomes may serve as a
useful tool for the diagnosis of lung cancer and ovarian
cancer,82,83 and recently a method for the isolation of mRNA
and miRNA for diagnostic purposes from urine exosomes
were developed.79 Even without enrichment by exosome
isolation, the abundances of several miRNAs (miR-200a,
miR-200b, and miR-429) were found to be decreased in
urinary sediments from patients with immunoglobulin A
nephropathy, and the degree of reduction correlated with the
severity of the disease.84
It may be possible to increase both the sensitivity and the
specificity of RNA biomarker approaches through the
enrichment of exosomes specific to the given cell type. Flow
cytometry approaches for the latter task are under develop-
ment.85,86
EXOSOMES AS POTENTIAL THERAPEUTIC AGENTS
The finding of mRNAs and miRNAs in exosomes and
evidence for a role for exosomes in cell–cell communication
(reviewed above) foreshadows an important new direction,
that is, the use of exosomes as delivery vehicles for
therapeutics. The concept is that RNA-bearing exosomes
can potentially deliver their contents to specific target cells in
order to transiently correct dysregulated processes.
Already, several researchers have preliminarily explored
the possibility of using exosomes as therapeutic delivery
vehicles. In 1998, Zitvogel et al.87 proposed the use of
exosomes in the immunotherapy of cancer, showing that
exosomes derived from tumor peptide-pulsed dendritic cells
injected into tumor-bearing mice resulted in eradication or
reduced growth of the tumor. More recently, others have
pioneered the application of exosomes in cancer treat-
ment.88,89 Two phase I clinical trials studied injection of
antigen-loaded exosomes from autologous dendritic cells
into patients with melanoma or lung cancer and demon-
strated feasibility and safety of exosome-based therapy,
although the effects on reduction of disease progression were
only minor.90,91 Similar approaches have the potential for
treatment of renal cancers.92
In 2007, Valadi et al.34 demonstrated that exosomes are
able to transfer miRNAs from their cell of origin to target
cells. Besides miRNAs, pre-miRNA could be identified in
mesenchymal stem cell-derived exosomes.93 Functionally, this
offers cells the possibility to increase (mRNA) or reduce
(miRNA, pre-miRNA) protein expression levels in specific
target cells. Transfer of mRNA and miRNA molecules to
target cells can influence their function, which may be the
mechanism by which endothelial progenitor cell-derived
exosomes stimulate angiogenesis in endothelial cells.77
Another potential use of exosomes is as vehicles for the
delivery of specific antigens. This approach has been applied
for vaccination against severe acute respiratory syndrome,
using exosomes containing the severe acute respiratory
syndrome S protein94 and against Toxoplasma gondii, using
antigen-containing exosomes.95 Both vaccines showed posi-
tive results, displayed as higher levels of neutralizing
antibodies and, in the T. gondii study, there was a reduction
of disease severity in mice.
Exosomes have been reported to be the active component
in the conditioned medium of mesenchymal stem cells that
display cardioprotective effects by reducing cardiac infarct
size after experimental ischemia–reperfusion.96 Cardiomyo-
cyte progenitor cell-derived exosomes may also have this
potential.12 A role for exosomes may be found in the
paracrine effects that have been observed in experimental
stem cell therapy. For example, in experimental stem cell
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therapy of acute kidney injury, mesenchymal stem cells have
been shown to improve recovery in part through paracrine
factors derived from secreted exosomes.97,98 In experimental
stem cell therapy of experimental glomerulonephritis in rats
(anti-Thy1.1 glomerulonephritis), Kunter et al.99 found a
benefit that they attributed to paracrine factors from the
injected mesenchymal stem cells rather than from the cells
themselves. Conceivably, exosome secretion is involved in
these observed paracrine effects.
For many kidney-related diseases, a prime target for
potential exosome-based therapy are endothelial cells, which
have essential roles in regulation of blood pressure, local
regulation of blood flow, regulation of blood clotting, and
clearance of plasma lipids. Failure of these processes is
responsible for a large fraction of common chronic diseases
that affect the kidney, including atheroslerosis and hyperten-
sion. Because the endothelial cells face the blood compart-
ment, they might be considered ‘low-hanging fruit’ for
potential exosome-based therapies, as the problem of
targeting is largely obviated.
On the basis of the above observations and additional
ongoing research, we conclude that exosomes have consider-
able promise for treatment of a variety of renal diseases. To
succeed, however, there is a need to develop methods for
efficient isolation of exosomes of appropriate composition,
allowing targeting to specific cell types and allowing transfer
of selected biomolecule cargos. This can only be achieved
through further basic research based on the following
questions: (1) How do multivescular bodies select biomole-
cules for inclusion in their intraluminal vesicles? (2) How do
exosomes interact with cell surfaces of some cells and not
others? (3) What is the mechanism of fusion of the limiting
membrane of exosomes with plasma membranes?, and (4)
How are exosomes in plasma normally cleared and how can
this process be selectively delayed for therapeutic exosomes?
CONCLUSION
Our objective in this short review has been to provide a brief
synopsis of knowledge about exosomes with a view toward
future exploitation in the diagnosis and therapy of kidney
diseases and kidney-related diseases. Nephrologists are in a
continual search for new tools to improve their ability to
rapidly and accurately diagnose renal disease via noninvasive
methodologies. The advent of sensitive and accurate MS and
genomics techniques has facilitated this quest, and it is likely
that in the near future several exosomal biomarkers will come
into play in clinical practice. Current efforts to replace
ultracentrifugation with more efficient exosome isolation
methods, such as filtration,100,101 size-exclusion chromato-
graphy,102 and affinity methods,103 can be expected to lead to
more practical protocols for the profiling of exosomal
proteins and RNAs. The potential use of exosomes as
therapeutic vehicles is based on the fact that exosome
secretion and reuptake can move molecules (and informa-
tion) between cells, processes that can be interrupted or
modified by design. Possibly, in the coming years, we can
extend this frontier beyond its current main focus in the areas
of oncology and immune diseases to achieve new ways to
treat kidney diseases and kidney-related diseases.
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